---
layout: default
title: Alfacalcidol
description: "Alfacalcidol 的老藥新用潛力分析。中等證據等級 L3，包含 5 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 中證據等級 (L3-L4)
nav_order: 14
evidence_level: L4
indication_count: 5
---

# Alfacalcidol

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L3</strong> | 預測適應症: <strong>5</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Alfacalcidol：從骨質疏鬆到腎小管酸中毒探索

## 一句話總結

<p class="key-answer" data-question="Alfacalcidol 可以用於治療什麼新適應症？">
Alfacalcidol 原本用於骨質疏鬆症及維生素 D 缺乏相關疾病。
TxGNN 模型預測它可能對**腎小管酸中毒 (renal tubular acidosis)** 有效，
目前有 **8 篇文獻**支持這個方向。
</p>


## 快速總覽

| 項目 | 內容 |
|------|------|
| 原適應症 | 骨質疏鬆症、慢性腎不全低血鈣症、副甲狀腺機能低下症、佝僂病、骨軟化症 |
| 預測新適應症 | familial isolated hypoparathyroidism due to impaired PTH secretion、Dahlberg-Borer-Newcomer syndrome、craniofacial conodysplasia、acromesomelic dysplasia, Campailla Martinelli type、hypoparathyroidism |
| TxGNN 預測分數 | 99.27% |
| 證據等級 | L3 |
| 台灣上市 | 已上市 |
| 許可證數 | 多張（部分已註銷） |
| 建議決策 | Proceed with Guardrails |






## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. familial isolated hypoparathyroidism due to impaired PTH secretion</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.61%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p>Alfacalcidol（1α-hydroxycholecalciferol）是活性維生素 D3 前驅物，在肝臟轉換為活性形式 1,25(OH)2D3（calcitriol）。其主要作用包括：</p>
<ol>
<li>促進腸道鈣磷吸收</li>
<li>調節骨代謝</li>
<li>抑制副甲狀腺素分泌</li>
<li>維持鈣磷恆定</li>

</ol>
<p>腎小管酸中毒 (RTA) 常導致慢性代謝性酸中毒，進而造成：</p>
<ul>
<li>骨骼礦物質流失</li>
<li>骨軟化症</li>
<li>生長遲緩（兒童）</li>
<li>低血鈣及低磷血症</li>

</ul>
<p>在 RTA 的治療中，除了鹼劑補充外，維生素 D 類藥物是重要的輔助治療，用於：</p>
<ol>
<li>預防及治療骨軟化症</li>
<li>改善鈣磷代謝異常</li>
<li>促進骨質恢復</li>

</ol>
<p>多篇文獻顯示 alfacalcidol 在 RTA 合併骨軟化症的患者中可有效改善骨密度及臨床症狀。</p>

<h3>臨床試驗</h3>

<p>目前無針對此特定適應症的臨床試驗登記。</p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. Dahlberg-Borer-Newcomer syndrome</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.60%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31485552/" target="_blank">31485552</a></td><td>2019</td><td>Article</td><td>JBMR plus</td><td>FGF23, Hypophosphatemia, and Emerging Treatments.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38802119/" target="_blank">38802119</a></td><td>2024</td><td>Article</td><td>Journal of inherited metabolic</td><td>Repurposing SGLT2 inhibitors: Treatment of renal proximal tubulopathy in Fanconi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16279662/" target="_blank">16279662</a></td><td>2005</td><td>Article</td><td>Nihon rinsho. Japanese journal</td><td>[Hypoparathyroidism].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39168248/" target="_blank">39168248</a></td><td>2024</td><td>Article</td><td>Virologica Sinica</td><td>Antiviral activity of vitamin D derivatives against severe fever with thrombocyt...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30333271/" target="_blank">30333271</a></td><td>2018</td><td>Article</td><td>Acta medica Indonesiana</td><td>Effect of Alfacalcidol on Inflammatory markers and T Cell Subsets in Elderly wit...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36412607/" target="_blank">36412607</a></td><td>2023</td><td>Article</td><td>Kidney &amp; blood pressure resear</td><td>Severe Hypophosphatemia as the Initial Presentation of Renal Fanconi&#x27;s Syndrome ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6262039/" target="_blank">6262039</a></td><td>1981</td><td>Article</td><td>Drugs</td><td>Pharmacology and therapeutic use of vitamin D and its analogues.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29545131/" target="_blank">29545131</a></td><td>2018</td><td>Article</td><td>Nephrologie &amp; therapeutique</td><td>[Utilization of alfacalcidol and active vitamin D analogs in chronic kidney dise...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34431511/" target="_blank">34431511</a></td><td>2021</td><td>Article</td><td>The Cochrane database of syste</td><td>Vitamin D supplementation for chronic liver diseases in adults.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37968949/" target="_blank">37968949</a></td><td>2023</td><td>Article</td><td>Problemy endokrinologii</td><td>[Clinical features, diagnostics and treatment of FGF23 secreting tumors: series ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39436634/" target="_blank">39436634</a></td><td>2024</td><td>Article</td><td>Metabolic brain disease</td><td>Exploring the material basis and molecular targets of Changma Xifeng tablet in t...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27904656/" target="_blank">27904656</a></td><td>2016</td><td>Article</td><td>The EPMA journal</td><td>The Berlin Treatment Algorithm: recommendations for tailored innovative therapeu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31968342/" target="_blank">31968342</a></td><td>2020</td><td>Article</td><td>American journal of nephrology</td><td>Calcium-Alkali Syndrome Associated with Hypoparathyroidism Following Total Thyro...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32299476/" target="_blank">32299476</a></td><td>2020</td><td>Article</td><td>Orphanet journal of rare disea</td><td>Natural history of non-lethal Raine syndrome during childhood.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24776629/" target="_blank">24776629</a></td><td>2014</td><td>Article</td><td>Hormones (Athens, Greece)</td><td>Hypocalcaemia following thyroidectomy unresponsive to oral therapy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28993435/" target="_blank">28993435</a></td><td>2017</td><td>Article</td><td>Endocrine connections</td><td>Impact of intercurrent illness on calcium homeostasis in children with hypoparat...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36279852/" target="_blank">36279852</a></td><td>2023</td><td>Article</td><td>Hormone research in paediatric</td><td>Burosumab Therapy in a Paediatric Patient with McCune-Albright Syndrome: A Case ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28509300/" target="_blank">28509300</a></td><td>2013</td><td>Article</td><td>CEN case reports</td><td>Pulmonary and gastric metastatic calcification due to milk-alkali syndrome: a ca...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28157691/" target="_blank">28157691</a></td><td>2017</td><td>Article</td><td>Hormone molecular biology and </td><td>The effect of alfacalcidiol and metformin on metabolic disturbances in women wit...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17506312/" target="_blank">17506312</a></td><td>2007</td><td>Article</td><td>Nihon Naika Gakkai zasshi. The</td><td>[Tumor-induced hypophosphatemic osteomalacia].</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. craniofacial conodysplasia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.55%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. acromesomelic dysplasia, Campailla Martinelli type</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.53%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. renal tubular acidosis</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.27%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（8 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36412607/" target="_blank">36412607</a></td><td>2023</td><td>Article</td><td>Kidney &amp; blood pressure resear</td><td>Severe Hypophosphatemia as the Initial Presentation of Renal Fanconi&#x27;s Syndrome ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28509074/" target="_blank">28509074</a></td><td>2012</td><td>Article</td><td>CEN case reports</td><td>Osteomalacia secondary to renal tubular acidosis due to Sjögren&#x27;s syndrome: a ca...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33398781/" target="_blank">33398781</a></td><td>2021</td><td>Article</td><td>CEN case reports</td><td>Osteomalacia caused by atypical renal tubular acidosis with vitamin D deficiency...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/11518137/" target="_blank">11518137</a></td><td>2001</td><td>Article</td><td>Internal medicine (Tokyo, Japa</td><td>Rapid improvement of osteomalacia by treatment in a case with Sjögren&#x27;s syndrome...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22740247/" target="_blank">22740247</a></td><td>2013</td><td>Article</td><td>Modern rheumatology</td><td>Successful treatment of osteomalacia caused by renal tubular acidosis associated...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6709109/" target="_blank">6709109</a></td><td>1984</td><td>Article</td><td>The Netherlands journal of med</td><td>A patient with 25-hydroxylation of 1-alpha-hydroxy vitamin D in primary biliary ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/9134837/" target="_blank">9134837</a></td><td>1997</td><td>Article</td><td>Nihon Jinzo Gakkai shi</td><td>[Long-term follow-up study of bone mineral density in a patient with adult idiop...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/6893175/" target="_blank">6893175</a></td><td>1980</td><td>Article</td><td>Contributions to nephrology</td><td>Biologic and therapeutic effects of 1 alpha-hydroxycholecalciferol in different ...</td></tr>
</tbody>
</table>

</div>
</details>


## 台灣上市資訊

| 許可證號 | 品名 | 劑型 | 核准適應症 |
|---------|------|------|-----------|
| 衛署藥製字第044609號 | 阿法鈣斯多 "台耀" | 粉劑 | 維他命 D 缺乏症 |
| 衛署藥製字第040333號 | "漁人" 腎骨全軟膠囊 0.25ug | 軟膠囊劑 | 骨質疏鬆症、慢性腎不全低血鈣症、副甲狀腺機能低下症、維生素 D 抵抗性佝僂病、骨軟化症 |
| 衛署藥輸字第024916號 | 萬乃補軟膠囊 | 軟膠囊劑 | 骨質疏鬆症、維他命 D 缺乏症 |
| 衛署藥輸字第023050號 | 骨精鈣膠囊 1.0ug | 軟膠囊劑 | 骨質疏鬆症、慢性腎不全低血鈣症、副甲狀腺機能低下症 |

## 安全性考量

### 重要藥物交互作用

**Moderate 交互作用：**
- 含鈣制酸劑（Calcium carbonate 等）：可能增加高鈣血症風險
- Digoxin：高鈣血症可增加毛地黃毒性
- Thiazide 利尿劑：增加高鈣血症風險
- Cholestyramine：減少 alfacalcidol 吸收
- Phenytoin、Phenobarbital：加速維生素 D 代謝
- Magnesium 類制酸劑（慢性腎病患者）：增加高鎂血症風險

### 監測項目
- 血清鈣（初期每週，穩定後每月）
- 血清磷
- 腎功能（Creatinine、BUN）
- 24 小時尿鈣（必要時）

### 高鈣血症症狀
- 噁心、嘔吐、便秘
- 多尿、口渴
- 肌肉無力
- 意識改變

安全性資訊請參考原廠仿單。

## 結論與下一步

**決策：Proceed with Guardrails**

**理由：**
Alfacalcidol 在腎小管酸中毒合併骨軟化症的治療中已有多篇個案報告支持其療效。作為活性維生素 D 衍生物，其能有效改善 RTA 患者因慢性酸中毒導致的鈣磷代謝異常及骨病變。在臨床實務上，alfacalcidol 常與鹼劑（如 sodium bicarbonate、potassium citrate）併用，作為 RTA 的標準治療組合。

**若要推進需要：**
- 同時補充鹼劑矯正代謝性酸中毒
- 密切監測血鈣，避免高鈣血症
- 監測腎功能及尿鈣排泄
- 考慮合併使用雙磷酸鹽類藥物改善骨密度
- 設計前瞻性研究，探討最佳劑量及治療時程


---

## 相關藥物報告

- [Ribavirin]({{ "/drugs/ribavirin/" | relative_url }}) - 證據等級 L3
- [Dorzolamide]({{ "/drugs/dorzolamide/" | relative_url }}) - 證據等級 L3
- [Interferon Beta-1B]({{ "/drugs/interferon_beta-1b/" | relative_url }}) - 證據等級 L3
- [Amcinonide]({{ "/drugs/amcinonide/" | relative_url }}) - 證據等級 L3
- [Durvalumab]({{ "/drugs/durvalumab/" | relative_url }}) - 證據等級 L3

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Alfacalcidol老藥新用驗證報告. https://twtxgnn.yao.care/drugs/alfacalcidol/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_alfacalcidol,
  title = {Alfacalcidol老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/alfacalcidol/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
